Xencor(XNCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XNCR Xencor

Trading 10-23 15:32:53 EDT

25.05

-0.79

-3.06%

High25.81	Low24.42	Vol628.94K
Open25.52	D1 Closing25.84	Amplitude5.38%
Mkt Cap1.86B	Tradable Cap1.36B	Total Shares74.13M
T/O15.67M	T/O Rate1.16%	Tradable Shares54.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XNCR","market":"US","secType":"STK","nameCN":"Xencor","latestPrice":25.05,"timestamp":1792783973269,"preClose":25.84,"halted":0,"volume":628939,"delay":0,"changeRate":-0.030572755417956624,"floatShares":54251400,"shares":74127400,"eps":-2.176824,"marketStatus":"Trading","change":-0.79,"latestTime":"10-23 15:32:53 EDT","open":25.52,"high":25.81,"low":24.42,"amount":15672332.196276,"amplitude":0.053793,"askPrice":25.07,"askSize":921,"bidPrice":25.03,"bidSize":233,"shortable":3,"etf":0,"ttmEps":-2.176824,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792785600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1386046800000,"exchange":"NASDAQ","adjPreClose":25.84,"preHourTrading":{"tag":"盘前","latestPrice":26.1687,"preClose":25.84,"latestTime":"09:14 EDT","volume":40,"amount":1060.46072,"timestamp":1792761291847,"change":0.3287,"changeRate":0.012721,"amplitude":0.094427},"postHourTrading":{"tag":"盘后","latestPrice":25.84,"preClose":25.84,"latestTime":"19:30 EDT","volume":31658,"amount":818006.51,"timestamp":1792711802210,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.522452,"impliedVol":1.4025,"impliedVolPercentile":0.8606},"requestUrl":"/m/hq/s/XNCR","defaultTab":"news","newsList":[{"id":"2677674492","title":"Xencor Price Target Maintained with a $30.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2677674492","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677674492?lang=en_us&edition=fundamental","pubTime":"2026-10-21 21:10","pubTimestamp":1792588200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XNCR/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677265786","title":"Xencor (XNCR) Following XmAb819 Webcast Plans, Is The Pipeline Narrative Starting To Look Undervalued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2677265786","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677265786?lang=en_us&edition=fundamental","pubTime":"2026-10-21 13:34","pubTimestamp":1792560867,"startTime":"0","endTime":"0","summary":"Xencor (XNCR) is moving back into focus after the company set an October 26 webcast to walk investors through Phase 1 data for its XmAb819 kidney cancer program and outlined a 2027 registration study.\nRecent trading reflects that backdrop. Xencor’s share price has rallied 7.6% over the past day and 27.8% across 90 days, contributing to a 67.2% year to date share price return. The 1 year total shareholder return of 71.9% points to strong momentum building around the pipeline story.\nCapitalize...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xncr/xencor/news/xencor-xncr-following-xmab819-webcast-plans-is-the-pipeline","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xncr/xencor/news/xencor-xncr-following-xmab819-webcast-plans-is-the-pipeline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676688395","title":"Xencor Plans Pivotal Study of XmAb819 in Advanced Kidney Cancer in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2676688395","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676688395?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:10","pubTimestamp":1792408259,"startTime":"0","endTime":"0","summary":"Xencor Plans Pivotal Study of XmAb819 in Advanced Kidney Cancer in 2027Xencor will present Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma at ESMO on October 25, 2026.Intraveno","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL2YCW8v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676002855","title":"Xencor to Host Webcast to Discuss Results from the Phase 1 Study of Xmab819 in Advanced Clear Cell Renal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2676002855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676002855?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:01","pubTimestamp":1792407660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nTUA2PRXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XNCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675584312","title":"Xencor (XNCR) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2675584312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675584312?lang=en_us&edition=fundamental","pubTime":"2026-10-15 19:56","pubTimestamp":1792065392,"startTime":"0","endTime":"0","summary":"In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Xencor, with a price target of $30.00. According to TipRanks, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xencor-xncr-receives-a-buy-from-wells-fargo-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xencor-xncr-receives-a-buy-from-wells-fargo-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3B42.SGD","LU0162691827.USD","LU0070302665.USD","LU0048573561.USD","LU0267386448.USD","LU0128525689.USD","LU1201861249.SGD","PGF","LU0208291251.USD","LU0289960550.SGD","BK4585","LU0154236417.USD","LU0314106906.USD","LU0417517546.SGD","LU1894683264.USD","LU0130517989.USD","LU0251131958.USD","LU0029864427.USD","LU0128525929.USD","LU1506573853.SGD","FTXO","KBWB","LU1363072403.SGD","LU0787776722.HKD","LU1280957306.USD","LU0980610538.SGD","IE000M9KFDE8.USD","LU1035773651.USD","LU1074936037.SGD","BK4501","LU0211327993.USD","LU0868494617.USD","LU0683600562.USD","LU0256863811.USD","LU0106831901.USD","XNCR","IYF","LU0211328371.USD","LU0310800379.SGD","LU0052756011.USD","LU1267930573.SGD","BK4559","LU0149725797.USD","LU1069347547.HKD","LU1668664300.SGD","TFNS","LU2236285917.USD","LU0648001328.SGD","LU0310799852.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671240053","title":"Wells Fargo Reaffirms Their Buy Rating on Xencor (XNCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671240053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671240053?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:15","pubTimestamp":1790720129,"startTime":"0","endTime":"0","summary":"In a report released today, from Wells Fargo maintained a Buy rating on Xencor, with a price target of $30.00. In addition to Wells Fargo, Xencor a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-reaffirms-their-buy-rating-on-xencor-xncr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-reaffirms-their-buy-rating-on-xencor-xncr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670256426","title":"Xencor Price Target Raised to $29.00/Share from $27.00 by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2670256426","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670256426?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:28","pubTimestamp":1790609280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XNCR/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234690","title":"Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and IQVIA Holdings (IQV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670234690?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:32","pubTimestamp":1790595120,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xencor (XNCR) and IQVIA Holdings (IQV) with bullish ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xencor-xncr-and-iqvia-holdings-iqv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xencor-xncr-and-iqvia-holdings-iqv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU1791710400.SGD","LABU","LU0128526141.USD","LU0130517989.USD","LU0477156953.USD","BK4137","XBI","BK4121","HEAL","LU0528227936.USD","BK4530","LU0648001328.SGD","LU0029874061.USD","XLV","EKG","LU0130518102.USD","LU1989764664.SGD","LU1261432733.SGD","LU0980610538.SGD","IQV","LU1791710582.SGD","LU1989764748.USD","LU0648000940.SGD","LU0477156797.USD","HCSG","LU0882574055.USD","BK4139","BK4588","BK4585","LU0130102774.USD","LU1201861165.SGD","LU1201861249.SGD","XNCR","LU0130103400.USD","LU0198837287.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670042966","title":"Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670042966","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670042966?lang=en_us&edition=fundamental","pubTime":"2026-09-26 01:33","pubTimestamp":1790357624,"startTime":"0","endTime":"0","summary":"Xencor's  upcoming dose-expansion data readout for XmAb819 to treat clear cell renal cell carcinoma has potential for improved response rates and more mature durability results, Wedbush Securities said in a Friday research report.XmAb819 has been evaluated in a more pretreated population, and meaningful activity in this setting could establish differentiation in efficacy and drive upside, according to the note.If the expansion cohort maintains the 25% overall response rate and 70% disease control rate already observed in dose-escalation, while dose-escalation cohorts show progression-free survival in line with or modestly above the established 6- to 7-month range, the drug remains on track for its registrational path, supporting continued appreciation of the stock, analysts wrote.Wedbush reiterated its outperform rating and a $30 price target on the stock.Price: 23.72, Change: -0.16, Percent Change: -0.69","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XNCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669637121","title":"BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2669637121","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669637121?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:20","pubTimestamp":1789993248,"startTime":"0","endTime":"0","summary":"Xencor (XNCR) has an average rating of overweight and mean price target of $31.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669215052","title":"Xencor price target raised to $26 from $20 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669215052","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669215052?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:40","pubTimestamp":1789987208,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on Xencor (XNCR) to $26 from $20 and keeps a Neutral rating on the shares. Despite falling off all-time highs o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-26-from-20-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-26-from-20-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666520901","title":"Xencor is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2666520901","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666520901?lang=en_us&edition=fundamental","pubTime":"2026-09-11 22:05","pubTimestamp":1789135500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XNCR/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528709","title":"Xencor price target raised to $35 from $27 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528709","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528709?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:35","pubTimestamp":1789119321,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Xencor (XNCR) to $35 from $27 and keeps an Overweight rating on the shares. The firm updated the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-35-from-27-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-35-from-27-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540057","title":"Xencor (XNCR) Receives a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666540057?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:16","pubTimestamp":1789118192,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on Xencor, with a price target of $35.00. Darout covers the Healthca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xencor-xncr-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xencor-xncr-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877239","title":"Xencor price target raised to $21 from $14 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877239?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:26","pubTimestamp":1788441990,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Brian Cheng raised the firm’s price target on Xencor (XNCR) to $21 from $14 and keeps a Neutral rating on the shares. The firm upd...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-21-from-14-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xencor-price-target-raised-to-21-from-14-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826999","title":"Xencor (XNCR) Could Be 6% Below Fair Value On Its Antibody Pipeline Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826999","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826999?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:27","pubTimestamp":1788406049,"startTime":"0","endTime":"0","summary":"Xencor (XNCR) is drawing fresh attention after management scheduled a presentation at the Cantor Global Healthcare Conference on September 9, 2026, as investors watch for any updates on its antibody pipeline.\nThe recent scheduling of Xencor’s Cantor presentation comes after a sharp shift in sentiment, with the stock giving back some ground in the last week. It has a 7 day share price return of 5.41% and a 1 day share price return of 3.62%, following a strong 30 day share price return of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xncr/xencor/news/xencor-xncr-could-be-6-below-fair-value-on-its-antibody-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xncr/xencor/news/xencor-xncr-could-be-6-below-fair-value-on-its-antibody-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XNCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846019","title":"Xencor to Present at Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846019","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664846019?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:01","pubTimestamp":1788379284,"startTime":"0","endTime":"0","summary":"Xencor to present at Cantor Global Healthcare ConferenceXencor will present at the Cantor Global Healthcare Conference on Sept. 9, 2026.The presentation is scheduled for 10:55 a.m. EDT.Disclaimer:This","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6vZ0d2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856828","title":"Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856828","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856828?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:49","pubTimestamp":1788263361,"startTime":"0","endTime":"0","summary":"Xencor (XNCR) has an average rating of buy and mean price target of $28.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RJF","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659660861","title":"Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR","url":"https://stock-news.laohu8.com/highlight/detail?id=2659660861","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659660861?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:31","pubTimestamp":1786638674,"startTime":"0","endTime":"0","summary":"Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. The Phase 1 trial A Phase 1 Trial, Evaluating the Safety and Tolerability ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xencor-advances-dual-antibody-cancer-trial-keeping-investor-focus-on-xncr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xencor-advances-dual-antibody-cancer-trial-keeping-investor-focus-on-xncr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBC","XNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658354779","title":"Analysts’ Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658354779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658354779?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:50","pubTimestamp":1786362616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xencor (XNCR), Revolution Medicines (RVMD) and Roiva...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-xencor-xncr-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-xencor-xncr-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE0002141913.USD","LU0029874061.USD","RVMD","BK4581","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4588","IDNA","XBI","LABU","XNCR","LU0109394709.USD","IE0009354923.USD","LU0128526141.USD","BBH","HCSG","XLV","LU0320765992.SGD","PTH","BK4139","IE00B2B36J28.USD","LU0889565916.HKD","BK4137","IE00BFTCPJ56.SGD","CANC","IE0009355771.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xencor.com","stockEarnings":[{"period":"1week","weight":0.0767},{"period":"1month","weight":0.027},{"period":"3month","weight":0.3292},{"period":"6month","weight":0.9908},{"period":"1year","weight":0.9443},{"period":"ytd","weight":0.6878}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0701},{"period":"1year","weight":0.144},{"period":"ytd","weight":0.1203}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.230769,"avgChangeRate":-0.060713},{"month":2,"riseRate":0.615385,"avgChangeRate":0.046082},{"month":3,"riseRate":0.230769,"avgChangeRate":-0.051854},{"month":4,"riseRate":0.153846,"avgChangeRate":-0.035695},{"month":5,"riseRate":0.538462,"avgChangeRate":0.016528},{"month":6,"riseRate":0.615385,"avgChangeRate":0.108196},{"month":7,"riseRate":0.615385,"avgChangeRate":0.020771},{"month":8,"riseRate":0.461538,"avgChangeRate":0.012524},{"month":9,"riseRate":0.384615,"avgChangeRate":0.008834},{"month":10,"riseRate":0.538462,"avgChangeRate":0.00805},{"month":11,"riseRate":0.916667,"avgChangeRate":0.149173},{"month":12,"riseRate":0.5,"avgChangeRate":0.005588}],"exchange":"NASDAQ","name":"Xencor","nameEN":"Xencor"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xencor(XNCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xencor(XNCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xencor,XNCR,Xencor股票,Xencor股票老虎,Xencor股票老虎国际,Xencor行情,Xencor股票行情,Xencor股价,Xencor股市,Xencor股票价格,Xencor股票交易,Xencor股票购买,Xencor股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xencor(XNCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xencor(XNCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}